Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies

Shin Mineishi, Yoshinobu Kanda, Takeshi Saito, Kunihisa Nakai, Atsushi Makimoto, Masahiro Kami, Ryuji Tanosaki, Hiro Wakasugi, Kensei Tobinai, Yoichi Takaue

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

To clarify the impact of graft-versus-host disease (GVHD) on the outcome of reduced-intensity stem cell transplantation (RIST), 40 patients who received RIST were compared with those who received conventional stem cell transplantation (CST). RIST regimens consisted of either cladribine (0.11 mg/kg/d × 6, n = 13) or fludarabine (30 mg/m2/d × 6, n = 27) with busulphan (BU, 4 mg/kg/d orally × 2), with or without antithymocyte globulin (ATG). CST regimens were either cyclophosphamide/total body irradiation (CY/TBI, n = 23), BU/CY (n = 19) or others (n = 6). The RIST group contained more patients who were at high risk of transplant-related mortality, including older patients, while the two groups contained the same percentages of patients at high risk of relapse. There were no differences between these groups in the incidences of acute (grade II-IV, 31.6% RIST vs 33.3% CST, P = 0.6742) and chronic GVHD (56.2% vs 64.1%, P = 0.8512), relapse rate (15.0% vs 18.8%, P = 0.6642), or overall (69.3% vs 65.6%, P = 0.4817) and progression-free survival (64.7% vs 63.8%, P = 0.6920) at d 500. Multivariate analysis of progression-free survival identified only grade III-IV acute GVHD and relapse risk dose as adverse risk factors. Although GVHD is a major threat in RIST, appropriate induction of GVHD may be associated with anti-tumour activity in RIST comparable to that of CST.

Original languageEnglish
Pages (from-to)296-303
Number of pages8
JournalBritish Journal of Haematology
Volume121
Issue number2
DOIs
Publication statusPublished - 2003 Apr
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Graft vs Host Disease
Hematologic Neoplasms
Recurrence
Disease-Free Survival
Cladribine
Busulfan
Antilymphocyte Serum
Whole-Body Irradiation
Cyclophosphamide
Multivariate Analysis
Transplants

Keywords

  • GVHD
  • GVL
  • Reduced-intensity stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. / Mineishi, Shin; Kanda, Yoshinobu; Saito, Takeshi; Nakai, Kunihisa; Makimoto, Atsushi; Kami, Masahiro; Tanosaki, Ryuji; Wakasugi, Hiro; Tobinai, Kensei; Takaue, Yoichi.

In: British Journal of Haematology, Vol. 121, No. 2, 04.2003, p. 296-303.

Research output: Contribution to journalArticle

Mineishi, Shin ; Kanda, Yoshinobu ; Saito, Takeshi ; Nakai, Kunihisa ; Makimoto, Atsushi ; Kami, Masahiro ; Tanosaki, Ryuji ; Wakasugi, Hiro ; Tobinai, Kensei ; Takaue, Yoichi. / Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. In: British Journal of Haematology. 2003 ; Vol. 121, No. 2. pp. 296-303.
@article{76fe4ccfc94f49aa8f9d3f946c6a4a68,
title = "Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies",
abstract = "To clarify the impact of graft-versus-host disease (GVHD) on the outcome of reduced-intensity stem cell transplantation (RIST), 40 patients who received RIST were compared with those who received conventional stem cell transplantation (CST). RIST regimens consisted of either cladribine (0.11 mg/kg/d × 6, n = 13) or fludarabine (30 mg/m2/d × 6, n = 27) with busulphan (BU, 4 mg/kg/d orally × 2), with or without antithymocyte globulin (ATG). CST regimens were either cyclophosphamide/total body irradiation (CY/TBI, n = 23), BU/CY (n = 19) or others (n = 6). The RIST group contained more patients who were at high risk of transplant-related mortality, including older patients, while the two groups contained the same percentages of patients at high risk of relapse. There were no differences between these groups in the incidences of acute (grade II-IV, 31.6{\%} RIST vs 33.3{\%} CST, P = 0.6742) and chronic GVHD (56.2{\%} vs 64.1{\%}, P = 0.8512), relapse rate (15.0{\%} vs 18.8{\%}, P = 0.6642), or overall (69.3{\%} vs 65.6{\%}, P = 0.4817) and progression-free survival (64.7{\%} vs 63.8{\%}, P = 0.6920) at d 500. Multivariate analysis of progression-free survival identified only grade III-IV acute GVHD and relapse risk dose as adverse risk factors. Although GVHD is a major threat in RIST, appropriate induction of GVHD may be associated with anti-tumour activity in RIST comparable to that of CST.",
keywords = "GVHD, GVL, Reduced-intensity stem cell transplantation",
author = "Shin Mineishi and Yoshinobu Kanda and Takeshi Saito and Kunihisa Nakai and Atsushi Makimoto and Masahiro Kami and Ryuji Tanosaki and Hiro Wakasugi and Kensei Tobinai and Yoichi Takaue",
year = "2003",
month = "4",
doi = "10.1046/j.1365-2141.2003.04281.x",
language = "English",
volume = "121",
pages = "296--303",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies

AU - Mineishi, Shin

AU - Kanda, Yoshinobu

AU - Saito, Takeshi

AU - Nakai, Kunihisa

AU - Makimoto, Atsushi

AU - Kami, Masahiro

AU - Tanosaki, Ryuji

AU - Wakasugi, Hiro

AU - Tobinai, Kensei

AU - Takaue, Yoichi

PY - 2003/4

Y1 - 2003/4

N2 - To clarify the impact of graft-versus-host disease (GVHD) on the outcome of reduced-intensity stem cell transplantation (RIST), 40 patients who received RIST were compared with those who received conventional stem cell transplantation (CST). RIST regimens consisted of either cladribine (0.11 mg/kg/d × 6, n = 13) or fludarabine (30 mg/m2/d × 6, n = 27) with busulphan (BU, 4 mg/kg/d orally × 2), with or without antithymocyte globulin (ATG). CST regimens were either cyclophosphamide/total body irradiation (CY/TBI, n = 23), BU/CY (n = 19) or others (n = 6). The RIST group contained more patients who were at high risk of transplant-related mortality, including older patients, while the two groups contained the same percentages of patients at high risk of relapse. There were no differences between these groups in the incidences of acute (grade II-IV, 31.6% RIST vs 33.3% CST, P = 0.6742) and chronic GVHD (56.2% vs 64.1%, P = 0.8512), relapse rate (15.0% vs 18.8%, P = 0.6642), or overall (69.3% vs 65.6%, P = 0.4817) and progression-free survival (64.7% vs 63.8%, P = 0.6920) at d 500. Multivariate analysis of progression-free survival identified only grade III-IV acute GVHD and relapse risk dose as adverse risk factors. Although GVHD is a major threat in RIST, appropriate induction of GVHD may be associated with anti-tumour activity in RIST comparable to that of CST.

AB - To clarify the impact of graft-versus-host disease (GVHD) on the outcome of reduced-intensity stem cell transplantation (RIST), 40 patients who received RIST were compared with those who received conventional stem cell transplantation (CST). RIST regimens consisted of either cladribine (0.11 mg/kg/d × 6, n = 13) or fludarabine (30 mg/m2/d × 6, n = 27) with busulphan (BU, 4 mg/kg/d orally × 2), with or without antithymocyte globulin (ATG). CST regimens were either cyclophosphamide/total body irradiation (CY/TBI, n = 23), BU/CY (n = 19) or others (n = 6). The RIST group contained more patients who were at high risk of transplant-related mortality, including older patients, while the two groups contained the same percentages of patients at high risk of relapse. There were no differences between these groups in the incidences of acute (grade II-IV, 31.6% RIST vs 33.3% CST, P = 0.6742) and chronic GVHD (56.2% vs 64.1%, P = 0.8512), relapse rate (15.0% vs 18.8%, P = 0.6642), or overall (69.3% vs 65.6%, P = 0.4817) and progression-free survival (64.7% vs 63.8%, P = 0.6920) at d 500. Multivariate analysis of progression-free survival identified only grade III-IV acute GVHD and relapse risk dose as adverse risk factors. Although GVHD is a major threat in RIST, appropriate induction of GVHD may be associated with anti-tumour activity in RIST comparable to that of CST.

KW - GVHD

KW - GVL

KW - Reduced-intensity stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0037541561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037541561&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04281.x

DO - 10.1046/j.1365-2141.2003.04281.x

M3 - Article

C2 - 12694252

AN - SCOPUS:0037541561

VL - 121

SP - 296

EP - 303

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -